Compare Crocs, Inc. (CROX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs GeneDx Holdings Corp — how do they compare? Crocs, Inc. trades at $131.17 (market cap $6.52B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Crocs, Inc. is far larger — about 3.5× GeneDx Holdings Corp's market cap, and Crocs, Inc. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| CROX | WGS | |
|---|---|---|
Market Cap | $6.52B | $1.85B |
Sector | Consumer Staples | Technology |
52-Week High | $132.78 | $167.51 |
52-Week Low | $73.39 | $34.51 |
Enterprise Value | $8.11B | $1.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $130.46, down 1.75% on the day, with strong technical momentum indicated by bullish moving averages and a potential breakout pattern forming. The company has consistently beaten earnings estimates in recent quarters, though 2025 showed a net loss of $81.20M. Strategic partnerships with LEGO and Disney are driving brand innovation, while international growth, particularly in Asia, provides expansion opportunities.
The stock presents a mixed outlook with bullish analyst sentiment (51% buy ratings) and a $131.29 consensus price target offering modest upside. Key risks include recent profitability challenges, high debt levels, and competitive pressures in the footwear sector. Revenue stability and brand strength support long-term potential, but margin recovery remains critical for sustained growth.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
